July 2025 in “Dermatology and Therapy” This study found that patients with alopecia areata showing low treatment burden responded better to baricitinib compared to those with higher previous systemic treatment exposure.
2 citations
,
February 2025 in “Archives of Dermatological Research” This retrospective study observed that switching from tofacitinib to baricitinib improved hair growth in patients with alopecia areata, particularly for previous non-responders, and noted fewer side effects with baricitinib.
14 citations
,
January 2025 in “Journal of Dermatological Treatment” In this multicenter retrospective study, 61.5% of Italian patients with severe alopecia areata achieved significant hair improvement after 52 weeks of treatment with baricitinib, with no major safety issues reported, indicating long-term effectiveness in a real-world setting.
1 citations
,
January 2025 in “Annals of Dermatology” In this study, baricitinib was well tolerated and led to clinical improvement in patients with treatment-resistant alopecia areata in a real-world clinical setting, suggesting it may be a potential treatment option.
April 2024 in “Frontiers in pharmacology” This study compared JAK inhibitors for moderate-to-severe alopecia areata and found brepocitinib 30mg and deuruxolitinib 12mg to be most effective, though deuruxolitinib may cause more adverse events. Further research is needed for long-term efficacy and safety.
12 citations
,
January 2024 in “Journal of the American Academy of Dermatology” 
December 2023 in “Journal of Cosmetic Dermatology” This study found that baricitinib, taken for 24 weeks, significantly reduced alopecia severity in patients with moderate-to-severe alopecia areata, with 50% showing marked improvement and overall favorable safety and efficacy reported.
7 citations
,
November 2023 in “JAAD Case Reports” This study highlights the recent FDA approval of baricitinib as the first on-label treatment for severe alopecia areata, whereas previous treatments were off-label therapies like systemic steroids and immunosuppressants.
21 citations
,
October 2023 in “Journal of Dermatological Treatment” The abstract provides a brief mention of alopecia areata (AA) being a chronic immune-mediated disorder causing non-scarring hair loss, but specific study results or findings relating to this are not reported.
September 2023 in “Dermatology and Therapy” In a Belgian cohort study, nearly 90% of alopecia areata patients treated with oral baricitinib experienced hair regrowth, with more than 70% achieving a favorable SALT score, particularly in patchy cases, though some relapsed post-treatment. No serious adverse events were noted.
20 citations
,
February 2023 in “American Journal of Clinical Dermatology” In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.
10 citations
,
January 2023 in “Journal of the European Academy of Dermatology and Venereology” This review highlights the significant negative impact of alopecia areata on quality of life, mental health, and work, calling for individualized approaches and effective treatments to mitigate these effects.
2 citations
,
January 2023 in “Prague Medical Report” This review examined the role, efficacy, and safety of Janus kinase inhibitors in treating alopecia areata, noting that baricitinib has received approval as the first on-label treatment due to positive outcomes in multiple trials.
116 citations
,
February 2017 in “Journal of the American Academy of Dermatology” This systematic review found that Janus kinase inhibitors have shown beneficial effects for psoriasis and alopecia areata, with promising preliminary results in other skin conditions, though more research is needed to define dosing and safety profiles.
355 citations
,
January 2017 in “Journal of the American Academy of Dermatology” This review reports no new results and highlights existing research suggesting JAK inhibitors may be effective in treating inflammatory skin conditions like alopecia areata, atopic dermatitis, psoriasis, and vitiligo.
40 citations
,
December 2016 in “Journal of Dermatological Treatment” This study reviewed the role of the JAK/STAT signaling pathway in skin diseases and the potential of JAK inhibitors for treating conditions like psoriasis and atopic dermatitis. Although the findings are promising, the authors concluded it is premature to establish their place in dermatological treatments.
132 citations
,
November 1998 in “Journal of the American Academy of Dermatology” This review evaluates the efficacy and safety of topical sensitizers in treating alopecia areata but reports no new clinical findings.
